Table 1 from Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. | Semantic Scholar
Frontiers | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi | Oncology
Development of vorinostat: current applications and future perspectives for cancer therapy. | Semantic Scholar
Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy… – Myeloma Research News
References in Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study - The Lancet Oncology
Vorinostat (SAHA) in clinical trials (N/A-not analyzed). | Download Scientific Diagram
Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta‑analysis of clinical trials
Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition | Cell Death & Disease
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells - Okubo - 2020 - Cancer Science - Wiley Online Library
Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma | British Journal of Cancer
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial - The Lancet Oncology
Vorinostat in single agent trials | Download Table
Summary of Phase I vorinostat trials | Download Table
Synthesis of benzoxazole-based vorinostat analogs and their antiproliferative activity - ScienceDirect
Vorinostat in published phase II clinical trials in solid tumors. | Download Table
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial - The Lancet Oncology
A trial of vorinostat for advanced mesothelioma | Cancer Research UK
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker | British Journal of Cancer
Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression
Clinical trials of vorinostat in combination therapy in patients with... | Download Table
Frontiers | Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent | Cell and Developmental Biology
Vorinostat - Wikipedia
Delivery systems for vorinostat in cancer treatment: An updated review - ScienceDirect
Vorinostat (SAHA) | HDAC Inhibitor | MedChemExpress
Targeting histone deacetylases: development of vorinostat for the treatment of cancer | Epigenomics
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies | Scientific Reports
